{"name":"Sol-Gel Technologies, Ltd.","slug":"sol-gel-technologies-ltd","ticker":"","exchange":"","domain":"sol-gel.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"S5G4T-2","genericName":"S5G4T-2","slug":"s5g4t-2","indication":"Acne vulgaris","status":"phase_3"},{"name":"S6G5T-3","genericName":"S6G5T-3","slug":"s6g5t-3","indication":"Acne vulgaris","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Efudex®","genericName":"Efudex®","slug":"efudex","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Patidegib Topical Gel","genericName":"Patidegib Topical Gel","slug":"patidegib-topical-gel","indication":"Basal cell carcinoma (topical treatment)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"S6G5T-8","genericName":"S6G5T-8","slug":"s6g5t-8","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"Efudex®","genericName":"Efudex®","slug":"efudex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"S5G4T-2","genericName":"S5G4T-2","slug":"s5g4t-2","phase":"phase_3","mechanism":"S5G4T-2 is a topical gel formulation of a retinoid, which works by modulating the activity of retinoic acid receptors in the skin.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Patidegib Topical Gel","genericName":"Patidegib Topical Gel","slug":"patidegib-topical-gel","phase":"phase_3","mechanism":"Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors.","indications":["Basal cell carcinoma (topical treatment)","Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"],"catalyst":""},{"name":"S6G5T-3","genericName":"S6G5T-3","slug":"s6g5t-3","phase":"phase_3","mechanism":"S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne.","indications":["Acne vulgaris"],"catalyst":""},{"name":"S6G5T-8","genericName":"S6G5T-8","slug":"s6g5t-8","phase":"phase_3","mechanism":"S6G5T-8 is a topical ophthalmic formulation designed to treat dry eye disease by promoting tear production and reducing ocular surface inflammation.","indications":["Dry eye disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPTWdkLXZqTVBOSkpkbFA0WHcyVzNqT0NVcTExN0ZsaDQxMnUxaHE2SDlRZUZ0UW04NWlhSkdCNDZWaEtoVzlrWnpGRi1hYUpQNzJlQnkyOUdXVlFEaDk2dlVfczVibXVHRXRaZTBERzdUMGl4MDBFVHZlNm1aTmQtck51aFdXYmlRdm5SOVFWdUJabjFwVnVpWGpWQnRldw?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Acne Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight - openPR.com","headline":"Acne Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNYnM0TmxtWEl6Zkl2U25iVlRMVXotTFNNY2lHSGIyV3QyX1pMc3A5a0tXOXkxSXZhdUJBc2JHS0hlUzF1WHczUGs1SlQ0U3JLRXRuSy1NdlQ3ak5PWW5Lb2NZQktTa3h3aGt2MURQVE0zQmY1UHB4V1E5OTQ0dTRQVkcwSHNRek5HQnBwdmxaaEMzSU1nRVVHUGNPdlZjSW8?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Leading Companies Fueling Growth and Innovation in the Actinic Keratosis Treatment Market - openPR.com","headline":"Leading Companies Fueling Growth and Innovation in the Actinic Keratosis Treatment Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPY3NwZEZTNW5NZVFQa3hTZkZDMzY4UWx4a0tmTUZjU1ZhdjhHa0xpa0JZcDJiM2U0VmZ2bzVIWXZUTVNfeHZEUFltX3hyT1dpenJ5elpyai1USk5VelZVUjU0RHF1SkNURWZFdV9QbTVJaE5ISDEtTkFrdkNFeEJ3WEpsQ3lYbjIxSDJEcmtiSTlSbVVfT2Z4TkJnd2diMURLRVBvcUxBRDhzWmlnZ3dPMW8tX244aFk?oc=5","date":"2026-03-31","type":"pipeline","source":"GuruFocus","summary":"Opaleye Management Inc. Increases Stake in Sol-Gel Technologies Ltd - GuruFocus","headline":"Opaleye Management Inc. Increases Stake in Sol-Gel Technologies Ltd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdkVhcVBsVDM3VmFSeXBIT1loSlpRV3FFTml2OURDTm9OVlVjTjIxV21CaVJoMm1mdWJjLThZWVgyMnU0c0tkWlVLeGZJX1dPWG0xSTQ5TmxWTHVabnJMUk5zLUdfRHBlR1BTLTlnVTJpd3RBc0ZiY2g1OXdEWDhmV2N3cDJPWFdwanBCYUVXNW9rdEdrUmZLVF9nOGxjTndGVEk2QUQ2UTRUUGltSmo2RFFmLUtRNEF0akdKdmx0T3NuZ2NPZ1NnTXFoZ25KcVlKUUxVMHhYYmI4c2RtSXBmZXQtcjFvZ2c?oc=5","date":"2026-03-25","type":"pipeline","source":"Proactive financial news","summary":"PreveCeutical advances drug delivery tech with Sol-Gel platform, eyes multi-asset spinouts - Proactive financial news","headline":"PreveCeutical advances drug delivery tech with Sol-Gel platform, eyes multi-asset spinouts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZ1Blc3MyZkFaaVMxdmR6Mm15QndfMGY0LXZpVEZPaW94aHZRcThQczlZNU5laElOZnBXUC1IUnJmZl9Qb3VnbG9WNC1ZUUlvNWV6eHJXX0tJckk3WUZCM3FFNzQwQy1oNnkzeC10ZGlVQmkzMlJqSmtBb0tIZExVNVk3WHp0eHhHQ0QtUWRsTTNSaEE3MkhEMjlVYWpYS1lBdVBUZjNrSk5HV1czeE1JQjl4ZUF1Q0xwa0RkY014UThIbmhwNm5rUzlkcVVwai1pSGc?oc=5","date":"2026-03-24","type":"pipeline","source":"Quiver Quantitative","summary":"Sol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary Shares - Quiver Quantitative","headline":"Sol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNbkszelpPaUVMREktaC1kSDY2aENNZlplTUNKY25KcDNoOGo0b01TcktCdzhhY2FzaW42bTEtd0lPVEQ3OHVDZ0dIay00ZFljWlFoVDRuZHB3LUNDMUtJMmsySkwzaTVpSl93M0FOdTVrbkJzTk1PSXdzZkJFbi1kRzF1SkFpaHNOOERncUNYNFJMc0FfR0tkN0dfSWhZLWgzcFNJX1d3TDJqdk42QmRfNzJaQWxjRmFBU0dUaA?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"Sol-Gel (NASDAQ: SLGL) prices $33.1M oversubscribed share offering - Stock Titan","headline":"Sol-Gel (NASDAQ: SLGL) prices $33.1M oversubscribed share offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQQ1hyejhNOG82V2xGb3BlaDl0UmNrOTQzN0huRTd3UG9ObENtUGxjcTJWNmtRNUtIdGVMNG5xZjNpSXdpeTNVN1ExdFh0ZXgxWTFzdDZ5Sko0ejhDYjJqN2xYLTlGaDMyc0lta1RTcVF1SndfWC1PZm1HUDN5b2Nnb1ItSkl2Nld4ZnpJX3djRlJqQlNKbnBhOUdaNmFfRHRvX0ZoazBtZXBSOFVEWjhBWGhpRlFZQQ?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"Sol-Gel brings in $33.1M to fund SGT-610 development - Stock Titan","headline":"Sol-Gel brings in $33.1M to fund SGT-610 development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBfYVdLNlgyZmwyV2o5bjltTVhQNXFBWGNzQWRpNlpERElVUlBkTWlSVmsxNmpOdEl5bmlWSFpUYlBSbFl4LTAxNW9hLXJkbElnY0ZqemFMdEdDMEdWQUdwQlJWSWp0b0JqX1RhZ1dYWkNOeHRlbkE?oc=5","date":"2026-01-30","type":"pipeline","source":"Fortune Business Insights","summary":"Rosacea Drugs Market Size, Share, Trends | Growth [2026-2034] - Fortune Business Insights","headline":"Rosacea Drugs Market Size, Share, Trends | Growth [2026-2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeWp4TDliM3pWTExSQlozOHRJQlZPZllHd2FwdU92bElqdEJpOXhoUVc1NkhnU1NTUzZzRm94WVZncUM2dy1rSTVYQlRoRGp0MzJWNDNuaklyUmZqay02Yi0taVdVZ09iTjFsYjZxUmJDLUd4TUZfQWxWbl9XMWp6SkFWdThubDRGOUZVSUFJNzlGcjBlWmJMblhRMm1FOUpwZ1FOSDhuc1pVd2VfOEQ5eDh3NVA2ZmoyOG5Kak4wbWk?oc=5","date":"2026-01-16","type":"earnings","source":"seekingalpha.com","summary":"Sol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 Catalyst - seekingalpha.com","headline":"Sol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 Catalyst","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Not At All Concerned With Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Not At All Concerned With Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-11","type":"earnings","source":"simplywall.st","summary":"Revenues Not Telling The Story For Sol-Gel Technologies Ltd. (NASDAQ:SLGL) After Shares Rise 30% - simplywall.st","headline":"Revenues Not Telling The Story For Sol-Gel Technologies Ltd. (NASDAQ:SLGL) After Shares Rise 30%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPU01PdmozZEdTS3d5SDhYVjJ6MlNodV9LaVVud0d1dW5OY1FTWXpyUkNEUnowdjVzM3VhRXpfLWx0cGNRYVdod0JpcmgyOVc0NldiMEFiVno5cmlNQkVjYzh5Z3ZUWWhxcDdOS0REMW5EdTA2b21PRjg0bFAxbV9nVnpqUUNHMG1KR0pTZGtyZWk1azU1LXNSQTYtbU5iYXJxZDFxRTR3b0dXYno3aDRZUWluZXRxcmNLZE5sMHliV0xvbF9IZmp1Uk1yd0lJU2JvMm5mazZWQkxLSG1Ba1Vod281aVNoQkJUYnl5dWRLTTUySF9LTnRBTmxKOWk?oc=5","date":"2025-10-27","type":"pipeline","source":"prnewswire.com","summary":"Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight - prnewswire.com","headline":"Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":1,"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}